BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 37244912)

  • 21. KDM3A/Ets1 epigenetic axis contributes to PAX3/FOXO1-driven and independent disease-promoting gene expression in fusion-positive Rhabdomyosarcoma.
    Sobral LM; Hicks HM; Parrish JK; McCann TS; Hsieh J; Goodspeed A; Costello JC; Black JC; Jedlicka P
    Mol Oncol; 2020 Oct; 14(10):2471-2486. PubMed ID: 32697014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of novel genes expressed during rhabdomyosarcoma differentiation using cDNA microarrays.
    Carey KA; Segal D; Klein R; Sanigorski A; Walder K; Collier GR; Cameron-Smith D
    Pathol Int; 2006 May; 56(5):246-55. PubMed ID: 16669873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting PAK4 Inhibits Ras-Mediated Signaling and Multiple Oncogenic Pathways in High-Risk Rhabdomyosarcoma.
    Dasgupta A; Sierra L; Tsang SV; Kurenbekova L; Patel T; Rajapakse K; Shuck RL; Rainusso N; Landesman Y; Unger T; Coarfa C; Yustein JT
    Cancer Res; 2021 Jan; 81(1):199-212. PubMed ID: 33168646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SPRY2 is a novel MET interactor that regulates metastatic potential and differentiation in rhabdomyosarcoma.
    Saini M; Verma A; Mathew SJ
    Cell Death Dis; 2018 Feb; 9(2):237. PubMed ID: 29445192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic Characterization, Current Model Systems and Prognostic Stratification in PAX Fusion-Negative vs. PAX Fusion-Positive Rhabdomyosarcoma.
    Dehner CA; Armstrong AE; Yohe M; Shern JF; Hirbe AC
    Genes (Basel); 2021 Sep; 12(10):. PubMed ID: 34680895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MiRNAs as Players in Rhabdomyosarcoma Development.
    Gasparini P; Ferrari A; Casanova M; Limido F; Massimino M; Sozzi G; Fortunato O
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31752446
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57
    Pomella S; Cassandri M; D'Archivio L; Porrazzo A; Cossetti C; Phelps D; Perrone C; Pezzella M; Cardinale A; Wachtel M; Aloisi S; Milewski D; Colletti M; Sreenivas P; Walters ZS; Barillari G; Di Giannatale A; Milano GM; De Stefanis C; Alaggio R; Rodriguez-Rodriguez S; Carlesso N; Vakoc CR; Velardi E; Schafer BW; Guccione E; Gatz SA; Wasti A; Yohe M; Ignatius M; Quintarelli C; Shipley J; Miele L; Khan J; Houghton PJ; Marampon F; Gryder BE; De Angelis B; Locatelli F; Rota R
    Nat Commun; 2023 Dec; 14(1):8373. PubMed ID: 38102140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of Notch3 signalling induces rhabdomyosarcoma cell differentiation promoting p38 phosphorylation and p21(Cip1) expression and hampers tumour cell growth in vitro and in vivo.
    Raimondi L; Ciarapica R; De Salvo M; Verginelli F; Gueguen M; Martini C; De Sio L; Cortese G; Locatelli M; Dang TP; Carlesso N; Miele L; Stifani S; Limon I; Locatelli F; Rota R
    Cell Death Differ; 2012 May; 19(5):871-81. PubMed ID: 22117196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation.
    Taulli R; Bersani F; Foglizzo V; Linari A; Vigna E; Ladanyi M; Tuschl T; Ponzetto C
    J Clin Invest; 2009 Aug; 119(8):2366-78. PubMed ID: 19620785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single-cell analysis and functional characterization uncover the stem cell hierarchies and developmental origins of rhabdomyosarcoma.
    Wei Y; Qin Q; Yan C; Hayes MN; Garcia SP; Xi H; Do D; Jin AH; Eng TC; McCarthy KM; Adhikari A; Onozato ML; Spentzos D; Neilsen GP; Iafrate AJ; Wexler LH; Pyle AD; Suvà ML; Dela Cruz F; Pinello L; Langenau DM
    Nat Cancer; 2022 Aug; 3(8):961-975. PubMed ID: 35982179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe.
    Hettmer S; Linardic CM; Kelsey A; Rudzinski ER; Vokuhl C; Selfe J; Ruhen O; Shern JF; Khan J; Kovach AR; Lupo PJ; Gatz SA; Schäfer BW; Volchenboum S; Minard-Colin V; Koscielniak E; Hawkins DS; Bisogno G; Sparber-Sauer M; Venkatramani R; Merks JHM; Shipley J
    Eur J Cancer; 2022 Sep; 172():367-386. PubMed ID: 35839732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SMYD1 and G6PD modulation are critical events for miR-206-mediated differentiation of rhabdomyosarcoma.
    Coda DM; Lingua MF; Morena D; Foglizzo V; Bersani F; Ala U; Ponzetto C; Taulli R
    Cell Cycle; 2015; 14(9):1389-402. PubMed ID: 25644430
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary Epithelioid Rhabdomyosarcoma of the Liver: Case Report of an Unusual Histological Variant.
    Nakamura H; Koyanagi Y; Kitamura M; Kukita Y
    Int J Surg Pathol; 2022 May; 30(3):331-334. PubMed ID: 34612734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deep Sequencing the microRNA profile in rhabdomyosarcoma reveals down-regulation of miR-378 family members.
    Megiorni F; Cialfi S; McDowell HP; Felsani A; Camero S; Guffanti A; Pizer B; Clerico A; De Grazia A; Pizzuti A; Moles A; Dominici C
    BMC Cancer; 2014 Nov; 14():880. PubMed ID: 25427715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The RNA helicase DDX5 cooperates with EHMT2 to sustain alveolar rhabdomyosarcoma growth.
    Gualtieri A; Bianconi V; Renzini A; Pieroni L; Licursi V; Mozzetta C
    Cell Rep; 2022 Aug; 40(9):111267. PubMed ID: 36044855
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Future directions in risk stratification and therapy for advanced pediatric genitourinary rhabdomyosarcoma.
    Harel M; Ferrer FA; Shapiro LH; Makari JH
    Urol Oncol; 2016 Feb; 34(2):103-15. PubMed ID: 26519985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.
    Olanich ME; Sun W; Hewitt SM; Abdullaev Z; Pack SD; Barr FG
    Clin Cancer Res; 2015 Nov; 21(21):4947-59. PubMed ID: 25810375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomyosarcoma cells.
    Niesen J; Brehm H; Stein C; Berges N; Pardo A; Fischer R; Ten Haaf A; Gattenlöhner S; Tur MK; Barth S
    J Cancer Res Clin Oncol; 2015 Jun; 141(6):1049-61. PubMed ID: 25433506
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology Group.
    Rodeberg DA; Garcia-Henriquez N; Lyden ER; Davicioni E; Parham DM; Skapek SX; Hayes-Jordan AA; Donaldson SS; Brown KL; Triche TJ; Meyer WH; Hawkins DS
    J Clin Oncol; 2011 Apr; 29(10):1304-11. PubMed ID: 21357792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Signaling pathways in Rhabdomyosarcoma invasion and metastasis.
    Ramadan F; Fahs A; Ghayad SE; Saab R
    Cancer Metastasis Rev; 2020 Mar; 39(1):287-301. PubMed ID: 31989508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.